Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C.

Nat Neurosci. 2009 Jul;12(7):826-8. doi: 10.1038/nn.2349. Epub 2009 Jun 7.

2.

A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

Robertson SD, Matthies HJ, Galli A.

Mol Neurobiol. 2009 Apr;39(2):73-80. doi: 10.1007/s12035-009-8053-4. Epub 2009 Feb 6. Review.

3.

LRRK2 regulates synaptic vesicle endocytosis.

Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, Kim KS, Chang S, Seol W.

Exp Cell Res. 2008 Jun 10;314(10):2055-65. doi: 10.1016/j.yexcr.2008.02.015. Epub 2008 Mar 5.

PMID:
18445495
4.

A Drosophila model for LRRK2-linked parkinsonism.

Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, Smith WW.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2693-8. doi: 10.1073/pnas.0708452105. Epub 2008 Feb 7.

5.

Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.

Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, Shen J.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11441-6. Epub 2007 Jun 11.

6.
7.

Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila.

Lee SB, Kim W, Lee S, Chung J.

Biochem Biophys Res Commun. 2007 Jun 29;358(2):534-9. Epub 2007 May 4.

PMID:
17498648
8.

GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T.

Biochemistry. 2007 Feb 6;46(5):1380-8.

PMID:
17260967
9.

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM.

Hum Mol Genet. 2007 Jan 15;16(2):223-32. Epub 2007 Jan 2.

PMID:
17200152
10.

Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL.

Ann Neurol. 2006 Nov;60(5):557-69.

PMID:
17120249
11.

The familial Parkinsonism gene LRRK2 regulates neurite process morphology.

MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A.

Neuron. 2006 Nov 22;52(4):587-93.

12.

A comparison between exocytic control mechanisms in adrenal chromaffin cells and a glutamatergic synapse.

Neher E.

Pflugers Arch. 2006 Dec;453(3):261-8. Epub 2006 Oct 3. Review.

PMID:
17016737
13.

Calcium signaling and exocytosis in adrenal chromaffin cells.

García AG, García-De-Diego AM, Gandía L, Borges R, García-Sancho J.

Physiol Rev. 2006 Oct;86(4):1093-131. Review.

14.

Kinase activity of mutant LRRK2 mediates neuronal toxicity.

Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA.

Nat Neurosci. 2006 Oct;9(10):1231-3. Epub 2006 Sep 17.

PMID:
16980962
15.

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR.

Neurobiol Dis. 2006 Aug;23(2):329-41. Epub 2006 Jun 5.

PMID:
16750377
16.

LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

Taylor JP, Mata IF, Farrer MJ.

Trends Mol Med. 2006 Feb;12(2):76-82. Epub 2006 Jan 10. Review.

PMID:
16406842
17.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

18.

Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohé CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V; Italian Parkinson's Genetics Network.

Eur J Hum Genet. 2006 Mar;14(3):322-31.

19.

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3.

20.

Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease.

Skipper L, Li Y, Bonnard C, Pavanni R, Yih Y, Chua E, Sung WK, Tan L, Wong MC, Tan EK, Liu J.

Hum Mol Genet. 2005 Dec 1;14(23):3549-56. Epub 2005 Nov 3.

PMID:
16269443

Supplemental Content

Support Center